Table 1 Characteristics of the TARGET cohort, Nanfang cohort and GSE7440.
TARGET (n = 124) | Nanfang cohort (n = 78) | GSE7440 (n = 59) | |
---|---|---|---|
Relapse | 98(79.0%) | 5(6.4%) | 31(52.5%) |
Age (Years), n(%) | |||
1–10 | 79(63.7%) | 64(82.1%) | |
10–18 | 45(36.3%) | 14(17.9%) | |
Gender | |||
Female | 58(46.8%) | 28(35.9%) | |
Male | 66(53.2%) | 50(64.1%) | |
WBC at Diagnosis, n(%) | |||
< 50 | 76(61.3%) | 69(88.5%) | |
> 50 | 48(38.7%) | 9(11.5%) | |
CNS status, n (%) | |||
1 | 101(81.5%) | 77(98.7%) | |
2 | 20(16.1%) | 0 | |
3 | 3(2.4%) | 1(1.3%) | |
Fusion gene, n(%) | |||
BCR::ABL | 3(2.4%) | 1(1.3%) | |
MLL-r | 2(1.6%) | 2(2.6%) | |
TCF3::PBX1 | 14(11.3%) | 3(3.8%) | |
ETV6::RUNX1 | 11(8.9%) | 10(12.8%) | |
Others | 29(23.4%) | 62(50%) | |
Unknown | 65(52.4%) | 0 | |
MRD at the end of induction, n(%) | |||
<0.01% | 78(63.0%) | 42(33.9%) | |
≥0.01% | 46(37.0%) | 36(29.0%) |